1. Home
  2. Clinical Evidence

Predictive Technologies

Control-IQ Technology

Oct 2021 - Candidate Selection for Hybrid Closed Loop Systems
Forlenza GP, Breton MD, Kovatchev BP.
Jun 2021 - Real-World Use of a New Hybrid Closed Loop Improves Glycemic Control in Youth with Type 1 Diabetes
Go to Publication
Mar 2021 - One Year Real-World Use of Control-IQ Advanced Hybrid Closed-Loop Technology
Go to Publication
Feb 2021 - A Virtual Training Program for the Tandem t:slim X2 Insulin Pump: Implementation and Outcomes
Go to Publication
Jan 2021 - Pediatric Diabetes "Initiating Hybrid Closed Loop: A Program Evaluation of an Educator-Led Control-IQ Follow-up at a Large Pediatric Clinic
Go to Publication
Dec 2020 - Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes
Go to Publication
Dec 2020 - Automated Insulin Delivery: Easy Enough to Use in Primary Care?
Go to Publication
Nov 2020 - Clinical Management and Pump Parameter Adjustment of the Control-IQ Closed-loop Control System
Go to Publication
Nov 2020 - Closed-Loop Insulin Therapy Improves Glycemic Control in Adolescents and Young Adults: Outcomes from the International Diabetes Closed-Loop (iDCL) Trial
Go to Publication
Nov 2020 - Significant Reduction in Time Below Range (Hypoglycemia) in People with Type 1 Diabetes Using an Advanced Hybrid Closed-Loop System
VIEW STUDY OVERVIEW
Sep 2020 - Psychosocial Impact of Control-IQ Technology in Pediatric Users with Type 1 Diabetes: Real-World Insights from the United States
View Study Overview
Sep 2020 - Real-World Patient-Reported Outcomes and Glycemic Results with Initiation of Control-IQ Technology
Go to Publication
Aug 2020 - Significant Improvements in Time Above Range Using Control-IQ Technology: Real-World Insights
View Study Overview
Aug 2020 - A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes
Go to Publication
Jun 2020 - Glycemic Outcomes for People with Type 1 and Type 2 Diabetes Using Control-IQ Technology: Real-World Data From Early Adopters
View Study Overview
Jun 2020 - Control-IQ Technology in the Real World: The First 30 days
View Study Overview
Jun 2020 - A Clinical Review of the t:slim X2 Insulin Pump
Go to Publication
May 2020 - Glycemic Outcomes of Use of Closed-Loop Control vs PLGS on Type 1 Diabetes: A Randomized Controlled Trial
Go to Publication
Oct 2019 - Six-Month Randomized, Multi-Center Trial of Closed-Loop Control in Type 1 Diabetes
Go to Publication
Jun 2019 - Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
Go to Publication
May 2019 - Closed-Loop Control in Adolescents and Children During Winter Sports: Use of the Tandem Control-IQ Artificial Pancreas System
Go to Publication
Apr 2019 - Successful At-Home Use of the Tandem Control-IQ Artificial Pancreas System in Young Children During a Randomized Controlled Trial
Go to Publication
Mar 2019 - Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials
Go to Publication
Feb 2019 - The International Diabetes Closed-Loop (IDCL) Study: Planned Pivotal Trials of Closed-Loop Control on an Embedded System and a Mobile System
Go to Publication
Dec 2018 - First Look at Control-IQ: A New Generation Automated Insulin Delivery System
Go to Publication
Aug 2017 - Closed-Loop Control During Intense Prolonged Outdoor Exercise in Adolescents With Type 1 Diabetes: The Artificial Pancreas Ski Study
Go to Publication
Nov 2015 - Measures of Risk and Glucose Variability in Adults Versus Youths
Go to Publication
May 2014 - Overnight Glucose Control With an Automated, Unified Safety System in Children and Adolescents With Type 1 Diabetes at Diabetes Camp
Go to Publication
Jan 2014 - Confusion Regarding Duration of Insulin Action: A Potential Source for Major Insulin Dose Errors by Bolus Calculators
Go to Publication

Basal-IQ Technology

Nov 2020 - Differences in Perceived Quality of Sleep and Satisfaction with Insulin Delivery Device in People With Diabetes
VIEW STUDY OVERVIEW
Aug 2020 - Basal-IQ Technology in the Real-World: Satisfaction and Reduction of Diabetes Burden in Individuals With Type 1 Diabetes
Go to Publication
Jul 2020 - Real-World Improvements in Hypoglycemia in an Insulin-Dependent Cohort Pre- and Post-Tandem Basal-IQ Technology Remote Software Update
Go to Publication
Jun 2020 - A Clinical Review of the t:slim X2 Insulin Pump
Go to Publication
May 2020 - Patient Perspectives on Satisfaction and Trust Related to Insulin Delivery Devices
View Study Overview
May 2020 - Psychosocial Benefits of Using Basal-IQ Predictive Low Glucose Suspend Technology in a Real-World Setting: Results From Pediatric Patients With Type 1 Diabetes
Go to Publication
May 2020 - Glycemic Outcomes of Use of Closed-Loop Control vs PLGS on Type 1 Diabetes: A Randomized Controlled Trial
Go to Publication
Nov 2019 - Real-World Patient Experience from 5,024 Patients Using the t:slim X2 Insulin Pump With Basal-IQ Technology
View Study Overview
Aug 2019 - Reducing Hypoglycemia in the Real World: A Retrospective Analysis of Predictive Low-Glucose Suspend Technology in an Ambulatory Insulin-Dependent Cohort
Go to Publication
Jun 2019 - Real-World Psychosocial Outcomes and Ease of Use Predict Trust in Automated Insulin Delivery Systems
View Study Overview
Jun 2019 - Early Real-World Hypoglycemia Outcomes With Use of the Tandem Basal-IQ Technology System
View Study Overview
Oct 2018 - Predictive Low Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study
Go to Publication

Product Documentation

Consult user guides for our pumps, infusion sets, predictive technology, and reporting app.

View Documentation

Product Training

Use our education tutorials to train your patients or CDEs on our easy-to-use products.

View Resources

Recommending

Recommending the t:slim X2 insulin pump is easy with our customized referral process and insurance benefits check.

Learn More

Responsible Use of Basal-IQ technology and Control-IQ technology

Systems like the t:slim X2 insulin pump with Basal-IQ technology and the t:slim X2 insulin pump with Control-IQ technology are not substitutes for active diabetes management. For example, users still must bolus for meals. Basal-IQ technology is designed to predict and help prevent lows, but it cannot prevent all lows and Basal-IQ technology does not predict high glucose events. Control-IQ technology is designed to predict and help prevent low and high glucose events, but it cannot prevent all highs and lows, and Control-IQ requires that users accurately input information, such as meals and periods of sleep or exercise. The Basal-IQ and Control-IQ features rely on continuous CGM readings and will not be able to predict glucose levels and adjust insulin dosing if the CGM is not working properly or is unable to communicate with the pump. Users must be sure to always use their pump, cartridges, CGM, and infusion sets as instructed and check them regularly to make sure they are working properly. Users should always pay attention to their symptoms, actively monitor and manage glucose levels, and treat according to prescriber recommendations.

Important Safety Information

The pump and each System below is indicated for use in individuals six years of age and greater. The pump and each System is intended for single user use. The pump and each System is indicated for use with NovoRapid, Admelog, or Humalog U-100 insulin.

The t:slim X2 insulin pump with Basal-IQ technology (the Basal-IQ System) consists of the t:slim X2 insulin pump, which contains Basal-IQ technology, and a compatible continuous glucose monitor (CGM, sold separately). The t:slim X2 insulin pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The t:slim X2 insulin pump can be used solely for continuous insulin delivery and as part of the Basal-IQ System. When used with a compatible CGM, the t:slim X2 insulin pump with Basal-IQ technology can be used to suspend insulin delivery based on CGM sensor readings.

The t:slim X2 insulin pump with Control-IQ technology (the Control-IQ System) consists of the t:slim X2 insulin pump, which contains Control-IQ technology, and a compatible continuous glucose monitor (CGM, sold separately). The t:slim X2 insulin pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The t:slim X2 insulin pump can be used solely for continuous insulin delivery and as part of the Control-IQ System. When used with a compatible CGM, the t:slim X2 insulin pump with Control-IQ technology can be used to automatically increase, decrease, and suspend delivery of basal insulin based on CGM sensor readings and predicted glucose values. The t:slim X2 insulin pump with Control-IQ technology can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. The t:slim X2 insulin pump with Control-IQ technology is intended for the management of Type 1 diabetes.

Warnings:

WARNING: Control-IQ technology should not be used by anyone under the age of six years old. It should also not be used in users who require less than 10 units of insulin per day or who weigh less than 25 kilograms.

 
Do not use the t:slim X2 insulin pump with Control-IQ technology if using hydroxyurea. Neither System is indicated for use in pregnant women, people on dialysis, or critically ill users. Users of the pump and either System must: be willing and able to use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts. The t:slim X2 pump and the CGM transmitter and sensor must be removed before MRI, CT, or diathermy treatment. Visit tandemdiabetes.com/safetyinfo for additional important safety information.